Page 1

Investor Contact : Megan Jones Exact Sciences Corp. meganjones@exactsciences.com 608-535-8815 Media Contact : Katie Boyce Exact Sciences Corp. kboyce@exactsciences.com 608-710-3903 For Immediate Release Exact Sciences Announces Second Quarter 2021 Results Exhibit 99 MADISON , Wis . , July 28 , 2021 - Exact Sciences Corp. ( Nasdaq : EXAS ) today announced that the company generated revenue of $ 434.8 million for the second quarter ended June 30 , 2021 , compared to $ 268.9 million for the same period of 2020 . " The Exact Sciences team remained unwavering in their dedication to our mission and delivered record results for CologuardⓇ and Oncotype DX® , " said Kevin Conroy , chairman and CEO . " We have a strong foundation in cancer screening and precision oncology and plan to transform cancer care with Cologuard , Oncotype , and our deep pipeline of innovative tests . " Second Quarter 2021 Financial Results For the three - month period ended June 30 , 2021 , as compared to the same period of 2020 ( where applicable ) : • . • • • Total revenue was $ 434.8 million , an increase of 62 percent Screening revenue was $ 263.9 million , an increase of 101 percent Screening revenue included a one - time downward adjustment of $ 12.1 million related to the passing of the contractual deadline to submit claims for previously completed Cologuard tests Precision Oncology revenue was $ 137.8 million , an increase of 34 percent COVID - 19 testing revenue was $ 33.1 million , a decrease of 4 percent Gross margin including amortization of acquired intangible assets was 69 % , and non - GAAP gross margin excluding amortization of acquired intangible assets was 74 % Net loss was $ 176.9 million , or $ 1.03 per share , compared to a net loss of $ 68.1 million , or $ 0.45 per share EBITDA was $ ( 122.9 ) million and adjusted EBITDA was $ ( 26.5 ) million Cash , cash equivalents , and marketable securities were $ 1.31 billion at the end of the quarter Screening includes laboratory service revenue from Cologuard tests and revenue from Biomatrica products . Precision Oncology includes laboratory service revenue from global Oncotype products and laboratory service revenue from Ashion . 2021 Outlook • • The company anticipates revenue of $ 1,705- $ 1,745 million during 2021 , including Screening revenue of $ 1,100- $ 1,125 million , Precision Oncology revenue of $ 530- $ 540 million , and COVID - 19 testing revenue of $ 75- $ 80 million . This is an increase from the previously expected revenue of $ 1,690- $ 1,735 million during 2021 , which included Screening revenue of $ 1,125- $ 1,150 million , Precision Oncology revenue of $ 515- $ 525 million , and COVID - 19 testing revenue of $ 50- $ 60 million . Lower Screening revenue expectations are primarily due to the one - time downward revenue adjustment of $ 12.1 million referenced above and COVID - 19 dynamics negatively impacting the business , including reduced physician office access for our field sales teams and fewer patient wellness visits . Non - GAAP Disclosure In addition to the company's financial results determined in accordance with U.S. GAAP , the company provides non - GAAP measures that it determines to be useful in evaluating its operating performance . The company presents EBITDA , adjusted EBITDA , as well as non - GAAP gross margin and non - GAAP gross profit . EBITDA and adjusted EBITDA consist of net loss